|
|
||||||||
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
This study focuses on the specific CD4+ T cell
requirement for optimal induction of cytotoxicity against MHC class II
negative autologous tumors (AuTu) collected from patients with various
types of cancer at advanced stages. CD4+ T cells were
induced in cultures of cancer patients malignant effusion-associated
mononuclear cells with irradiated AuTu (mixed lymphocyte tumor cultures
(MLTC)) in the presence of recombinant IL-2 and recombinant IL-7.
Tumor-specific CD4+ T cells did not directly recognize the
AuTu cells, but there was an MHC class II-restricted cross-priming by
autologous dendritic cells (DCs), used as APC. CD8+ CTL,
also induced during the MLTC, lysed specifically AuTu cells or DCs
pulsed with AuTu peptide extracts (acid wash extracts (AWE)) in an MHC
class I-restricted manner. Removal of CD4+ T cells or DCs
from the MLTC drastically reduced the CD8+ CTL-mediated
cytotoxic response against the AuTu. AWE-pulsed DCs preincubated with
autologous CD4+ T cells were able, in the absence of
CD4+ T cells, to stimulate CD8+ T cells to lyse
autologous tumor targets. Such activated CD8+ T cells
produced IL-2, IFN-
, TNF-
, and GM-CSF. The process of the
activation of AWE-pulsed DCs by CD4+ T cells could be
inhibited with anti-CD40 ligand mAb. Moreover, the role of
CD4+ T cells in activating AWE-pulsed DCs was undertaken by
anti-CD40 mAb. Our data demonstrate for the first time in patients
with metastatic cancer the essential role of CD4+ Th
cell-activated DCs for optimal CD8+ T cell-mediated killing
of autologous tumors and provide the basis for the design of novel
protocols in cellular adoptive immunotherapy of cancer, utilizing
synthetic peptides capable of inducing T cell help in
vivo.
This article has been cited by other articles:
![]() |
A. D. Gritzapis, I. F. Voutsas, E. Lekka, N. Tsavaris, I. Missitzis, P. Sotiropoulou, S. Perez, M. Papamichail, and C. N. Baxevanis Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties J. Immunol., July 1, 2008; 181(1): 146 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Cools, P. Ponsaerts, V. F. I. Van Tendeloo, and Z. N. Berneman Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells J. Leukoc. Biol., December 1, 2007; 82(6): 1365 - 1374. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Vujanovic, M. Mandic, W. C. Olson, J. M. Kirkwood, and W. J. Storkus A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6 Clin. Cancer Res., November 15, 2007; 13(22): 6796 - 6806. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. S. Zimmermann, A. Casati, C. Schiering, S. Caserta, R. Hess Michelini, V. Basso, and A. Mondino Tumors Hamper the Immunogenic Competence of CD4+ T Cell-Directed Dendritic Cell Vaccination J. Immunol., September 1, 2007; 179(5): 2899 - 2909. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, D. Wakita, K. Chamoto, Y. Narita, N. Matsubara, H. Kitamura, and T. Nishimura Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs Int. Immunol., February 1, 2007; 19(2): 151 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Montagna, L. Daudt, F. Locatelli, E. Montini, I. Turin, D. Lisini, G. Giorgiani, M. E. Bernardo, and R. Maccario Single-Cell Cloning of Human, Donor-Derived Antileukemia T-Cell Lines for In vitro Separation of Graft-versus-Leukemia Effect from Graft-versus-Host Reaction. Cancer Res., July 15, 2006; 66(14): 7310 - 7316. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Gritzapis, L. G. Mahaira, S. A. Perez, N. T. Cacoullos, M. Papamichail, and C. N. Baxevanis Vaccination with Human HER-2/neu (435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor Cells In vivo. Cancer Res., May 15, 2006; 66(10): 5452 - 5460. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Valmori, F. Qian, M. Ayyoub, C. Renner, A. Merlo, S. Gjnatic, E. Stockert, D. Driscoll, S. Lele, L. J. Old, et al. Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells Clin. Cancer Res., January 15, 2006; 12(2): 398 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Moeller, N. M. Haynes, M. H. Kershaw, J. T. Jackson, M. W. L. Teng, S. E. Street, L. Cerutti, S. M. Jane, J. A. Trapani, M. J. Smyth, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection Blood, November 1, 2005; 106(9): 2995 - 3003. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Slager, C. E. van der Minne, M. Kruse, D. D. Krueger, M. Griffioen, and S. Osanto Identification of Multiple HLA-DR-Restricted Epitopes of the Tumor-Associated Antigen CAMEL by CD4+ Th1/Th2 Lymphocytes J. Immunol., April 15, 2004; 172(8): 5095 - 5102. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Maraskovsky, S. Sjolander, D. P. Drane, M. Schnurr, T. T. T. Le, L. Mateo, T. Luft, K.-A. Masterman, T.-Y. Tai, Q. Chen, et al. NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors Clin. Cancer Res., April 15, 2004; 10(8): 2879 - 2890. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Hanson, S. S. Kang, L. A. Norian, K. Matsui, L. A. O'Mara, and P. M. Allen CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors J. Immunol., April 1, 2004; 172(7): 4215 - 4224. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. de Rijke, H. Fredrix, A. Zoetbrood, F. Scherpen, H. Witteveen, T. de Witte, E. van de Wiel-van Kemenade, and H. Dolstra Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy Blood, October 15, 2003; 102(8): 2885 - 2891. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Baxevanis, A. D. Gritzapis, and M. Papamichail In Vivo Antitumor Activity of NKT Cells Activated by the Combination of IL-12 and IL-18 J. Immunol., September 15, 2003; 171(6): 2953 - 2959. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsuboi, K. Saijo, E. Ishikawa, H. Tsurushima, S. Takano, Y. Morishita, and T. Ohno Effects of Local Injection of ex Vivo Expanded Autologous Tumor-specific T Lymphocytes in Cases with Recurrent Malignant Gliomas Clin. Cancer Res., August 1, 2003; 9(9): 3294 - 3302. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Perez, P. A. Sotiropoulou, D. G. Gkika, L. G. Mahaira, D. K. Niarchos, A. D. Gritzapis, Y. G. Kavalakis, A. I. Antsaklis, C. N. Baxevanis, and M. Papamichail A novel myeloid-like NK cell progenitor in human umbilical cord blood Blood, May 1, 2003; 101(9): 3444 - 3450. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yasukawa, H. Ohminami, K. Kojima, T. Hato, A. Hasegawa, T. Takahashi, H. Hirai, and S. Fujita HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes Blood, September 1, 2001; 98(5): 1498 - 1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. McNeel, L. D. Nguyen, and M. L. Disis Identification of T Helper Epitopes from Prostatic Acid Phosphatase Cancer Res., July 1, 2001; 61(13): 5161 - 5167. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Novak, S. A. Masewicz, A. W. Liu, A. Lernmark, W. W. Kwok, and G. T. Nepom Activated human epitope-specific T cells identified by class II tetramers reside within a CD4high, proliferating subset Int. Immunol., June 1, 2001; 13(6): 799 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Agrawal, J. Marquet, J. Plumas, H. Rouard, M.-H. Delfau-Larue, P. Gaulard, L. Boumsell, F. Reyes, A. Bensussan, and J.-P. Farcet Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue Int. Immunol., April 1, 2001; 13(4): 441 - 450. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zoller and O. Christ Prophylactic Tumor Vaccination: Comparison of Effector Mechanisms Initiated by Protein Versus DNA Vaccination J. Immunol., March 1, 2001; 166(5): 3440 - 3450. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Polakos, D. Drane, J. Cox, P. Ng, M. J. Selby, D. Chien, D. T. O'Hagan, M. Houghton, and X. Paliard Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine J. Immunol., March 1, 2001; 166(5): 3589 - 3598. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-A. Chen, M.-H. T. F.-T. Wu, A. Hsiang, Y.-L. Chen, H.-Y. Lei, T.-S. Tzai, H. W. C. Leung, Y.-T. Jin, C.-L. Hsieh, L.-H. Hwang, et al. Induction of Antitumor Immunity with Combination of HER2/neu DNA Vaccine and Interleukin 2 Gene-modified Tumor Vaccine Clin. Cancer Res., November 1, 2000; 6(11): 4381 - 4388. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, M. Bendandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L. W. Kwak, and H. K. Lyerly Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells Blood, October 15, 2000; 96(8): 2828 - 2833. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |